John Hardman1,2, ZiWei Liu1, Grainne Brady3, Justin Roe3,4, Cyrus Kerawala1, Francesco Riva1, Peter Clarke1,5, Dae Kim1,2, Shreerang Bhide1,2, Christopher Nutting1,2, Kevin Harrington1,2, Vinidh Paleri1,2. 1. Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK. 2. Institute of Cancer Research, London, UK. 3. Department of Speech and Language Therapy, The Royal Marsden NHS Foundation Trust, London, UK. 4. Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, UK. 5. Department of Otolaryngology, Head and Neck Surgery, Imperial College Healthcare NHS Trust, London, UK.
Abstract
BACKGROUND: Transoral robotic surgery (TORS) for recurrent head and neck (H&N) cancer is an emerging but relatively infrequent procedure. METHODS: Systematic review and meta-analysis of studies reporting survival data and functional outcomes for patients undergoing TORS for previously treated H&N cancers. RESULTS: Eight hundred seventy-eight records were identified, of which eight were eligible for inclusion, covering 161 cases (range 1-64). The pooled rates were as follows: 2-year overall survival 73.8% (4 studies, range 70.6-75.0, 95% confidence intervals (CI) 65.4 to 81.5, [I2 0.0%, P = 1.0]); 2-year disease-free survival 74.8% (4 studies, range 56.2-92.0, 95% CI 63.3 to 84.8, [I2 36.9%, P = .2]); postoperative hemorrhage 9.3% (4 studies, range 3.3-13.3, 95% CI 4.7 to 15.1, [I2 0.0%, P = .5]). CONCLUSIONS: Functional and oncological outcomes are favorable, although the follow-up is limited in the literature. Larger cohorts with longer follow-up are needed for definitive conclusions to be drawn.
BACKGROUND: Transoral robotic surgery (TORS) for recurrent head and neck (H&N) cancer is an emerging but relatively infrequent procedure. METHODS: Systematic review and meta-analysis of studies reporting survival data and functional outcomes for patients undergoing TORS for previously treated H&N cancers. RESULTS: Eight hundred seventy-eight records were identified, of which eight were eligible for inclusion, covering 161 cases (range 1-64). The pooled rates were as follows: 2-year overall survival 73.8% (4 studies, range 70.6-75.0, 95% confidence intervals (CI) 65.4 to 81.5, [I2 0.0%, P = 1.0]); 2-year disease-free survival 74.8% (4 studies, range 56.2-92.0, 95% CI 63.3 to 84.8, [I2 36.9%, P = .2]); postoperative hemorrhage 9.3% (4 studies, range 3.3-13.3, 95% CI 4.7 to 15.1, [I2 0.0%, P = .5]). CONCLUSIONS: Functional and oncological outcomes are favorable, although the follow-up is limited in the literature. Larger cohorts with longer follow-up are needed for definitive conclusions to be drawn.
Authors: John C Hardman; F Chris Holsinger; Grainne C Brady; Avinash Beharry; Alec T Bonifer; Gregoire D'Andréa; Surender K Dabas; John R de Almeida; Umamaheswar Duvvuri; Peter Floros; Tamer A Ghanem; Philippe Gorphe; Neil D Gross; David Hamilton; Chareeni Kurukulasuriya; Mikkel Hjordt Holm Larsen; Daniel J Lin; J Scott Magnuson; Jeroen Meulemans; Brett A Miles; Eric J Moore; Gouri Pantvaidya; Scott Roof; Niclas Rubek; Christian Simon; Anand Subash; Michael C Topf; Kathryn M Van Abel; Vincent Vander Poorten; Evan S Walgama; Emily Greenlay; Laura Potts; Arun Balaji; Heather M Starmer; Sarah Stephen; Justin Roe; Kevin Harrington; Vinidh Paleri Journal: J Natl Cancer Inst Date: 2022-10-06 Impact factor: 11.816